These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 23486071)
1. A cervical abnormality risk prediction model: can we use clinical information to predict which patients with ASCUS/LSIL Pap tests will develop CIN 2/3 or AIS? Charlton BM; Carwile JL; Michels KB; Feldman S J Low Genit Tract Dis; 2013 Jul; 17(3):242-7. PubMed ID: 23486071 [TBL] [Abstract][Full Text] [Related]
2. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? Ferris DG; Wright TC; Litaker MS; Richart RM; Lorincz AT; Sun XW; Borgatta L; Buck H; Kramer L; Rubin R J Fam Pract; 1998 Feb; 46(2):125-34. PubMed ID: 9487318 [TBL] [Abstract][Full Text] [Related]
3. The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results. Guo M; Gong Y; Wang J; Dawlett M; Patel S; Liu P; Bevers TB; Sneige N Cancer Cytopathol; 2013 Feb; 121(2):79-85. PubMed ID: 23225501 [TBL] [Abstract][Full Text] [Related]
4. Screening properties of human papillomavirus testing for predicting cervical intraepithelial neoplasia in atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion smears: a prospective study. Dane C; Batmaz G; Dane B; Cetin A Ann Diagn Pathol; 2009 Apr; 13(2):73-7. PubMed ID: 19302953 [TBL] [Abstract][Full Text] [Related]
5. Patients with negative cervical biopsies after papanicolaou test interpretations of "atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion": comparative longitudinal follow-up. Huitron S; Bonvicino A; Fadare O Ann Diagn Pathol; 2008 Jun; 12(3):187-90. PubMed ID: 18486894 [TBL] [Abstract][Full Text] [Related]
6. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia. Liao SY; Stanbridge EJ Cancer; 2000 Mar; 88(5):1108-21. PubMed ID: 10699902 [TBL] [Abstract][Full Text] [Related]
7. Risk of cervical intraepithelial neoplasia 2+ among women with a history of previous treatment for cervical intraepithelial neoplasia: ASCUS and LSIL Pap smears after treatment. Burks HR; Smith KM; Wentzensen N; Tenney M; Tuller E; Moxley K; Mathews C; Dunn ST; Wang SS; Gold MA J Low Genit Tract Dis; 2011 Jan; 15(1):11-4. PubMed ID: 21192170 [TBL] [Abstract][Full Text] [Related]
8. Improved abnormal Pap smear triage using cervical cancer biomarkers. Killeen JL; Dye T; Grace C; Hiraoka M J Low Genit Tract Dis; 2014 Jan; 18(1):1-7. PubMed ID: 23760145 [TBL] [Abstract][Full Text] [Related]
9. Managing atypical squamous cells of undetermined significance in Papanicolaou smears. Morin C; Bairati I; Bouchard C; Fortier M; Roy M; Moore L; Meisels A J Reprod Med; 2001 Sep; 46(9):799-805. PubMed ID: 11584480 [TBL] [Abstract][Full Text] [Related]
10. Is the human papillomavirus test in combination with the Papanicolaou test useful for management of patients with diagnoses of atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesions? Lee NW; Kim D; Park JT; Kim A Arch Pathol Lab Med; 2001 Nov; 125(11):1453-7. PubMed ID: 11698001 [TBL] [Abstract][Full Text] [Related]
11. Combined p16INK4a and human papillomavirus testing improves the prediction of cervical intraepithelial neoplasia (CIN II-III) in Thai patients with low-grade cytological abnormalities. Ekalaksananan T; Pientong C; Kongyingyoes B; Chaiwongkot A; Yuenyao P; Kleebkaow P; Kritpetcharat O; Evans MF Asian Pac J Cancer Prev; 2011; 12(7):1777-83. PubMed ID: 22126564 [TBL] [Abstract][Full Text] [Related]
12. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. Ferris DG; Wright TC; Litaker MS; Richart RM; Lorincz AT; Sun XW; Woodward L J Fam Pract; 1998 Feb; 46(2):136-41. PubMed ID: 9487319 [TBL] [Abstract][Full Text] [Related]
13. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309 [TBL] [Abstract][Full Text] [Related]
14. Comparison of conventional and liquid-based Pap smear methods in the diagnosis of precancerous cervical lesions. Honarvar Z; Zarisfi Z; Salari Sedigh S; Masoumi Shahrbabak M J Obstet Gynaecol; 2022 Aug; 42(6):2320-2324. PubMed ID: 35579303 [TBL] [Abstract][Full Text] [Related]
15. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral. Fait G; Kupferminc MJ; Daniel Y; Geva E; Ron IG; Lessing JB; Bar-Am A Gynecol Oncol; 2000 Nov; 79(2):177-80. PubMed ID: 11063640 [TBL] [Abstract][Full Text] [Related]
16. Should all women with cervical atypia be referred for colposcopy: a HARNET study. Harrisburgh Area Research Network. Slawson DC; Bennett JH; Simon LJ; Herman JM J Fam Pract; 1994 Apr; 38(4):387-92. PubMed ID: 8163964 [TBL] [Abstract][Full Text] [Related]
17. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance, after six months delay: a three-year experience in an Iranian university hospital. Yarandi F; Shojaei H; Eftekhar Z; Izadi-Mood N Aust N Z J Obstet Gynaecol; 2009 Apr; 49(2):207-10. PubMed ID: 19432613 [TBL] [Abstract][Full Text] [Related]
18. CIN 2/3 and cervical cancer after an ASCUS pap smear. A 7-year, prospective study of the Norwegian population-based, coordinated screening program. Nygård JF; Sauer T; Skjeldestad FE; Skare GB; Thoresen SØ Acta Cytol; 2003; 47(6):991-1000. PubMed ID: 14674068 [TBL] [Abstract][Full Text] [Related]
19. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153 [TBL] [Abstract][Full Text] [Related]
20. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening. Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]